Compimet 500: Each tablet contains Pioglitazone Hydrochloride INN 16.53 mg equivalent to Pioglitazone 15 mg and Metformin Hydrochloride BP 500 mg.
Compimet 850: Each tablet contains Pioglitazone Hydrochloride INN 16.53 mg equivalent to Pioglitazone 15 mg and Metformin Hydrochloride BP 850 mg.
Pioglitazone, for its mechanism of action, depends on the presence of insulin. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating PPAR-g receptor.
Metformin Hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
The initial and maintenance dose of Compimet should be carefully selected in patients with advanced age due to the potential for decreased renal function in these populations. Monitoring of renal function is necessary to aid in prevention of Metformin associated lactic acidosis, particularly in the elderly. Compimet should not be initiated if the patients exhibit clinical evidence of active liver disease. Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with combination of Pioglitazone and Metformin and periodically thereafter.
Metformin is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus patients with serum creatinine levels above the upper limit of normal for their age should not receive this combination.
1. Renal disease or renal dysfunction (e.g. as suggested by serum creatinine levels >1.5 mg/dl in male, >1.4 mg/dl in females or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction and septicemia.
2. Known hypersensitivity to Pioglitazone, Metformin or any other component of this combination.
3. Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma.
Nursing mother: It is not known whether Pioglitazone and/or Metformin are secreted in human milk. Because many drugs are excreted in human milk, this combination should not be administered to a breastfeeding woman.
Compimet 850: Each box contains 3 blister strips of 10 tablets.
Safety and efficacy of this preparation in pediatric patients have not been established.